• Viral infections

Veklury Generic Name & Formulations

General Description

Remdesivir 100mg/vial lyophilized pwd for IV infusion after reconstitution and dilution; or 100mg/20mL (5mg/mL) soln for IV infusion after dilution; preservative-free.

Pharmacological Class

SARS-CoV-2 nucleotide analogue RNA polymerase inhibitor.

How Supplied

Single-dose vial—1


Generic Availability


Veklury Indications


COVID-19 in patients with positive results of direct SARS-CoV-2 viral testing who are: hospitalized, or not hospitalized and have mild to moderate COVID-19 and are at high risk for progression to severe COVID-19, including hospitalization or death.

Veklury Dosage and Administration

Adults and Children

<28 days of age or <3kg: not established. Give by IV infusion over 30–120mins. ≥28 days of age (3–<40kg): Initially 5mg/kg on Day 1, followed by 2.5mg/kg once daily Day 2; (≥40kg): Initially 200mg once on Day 1, followed by 100mg once daily from Day 2. Hospitalized patients not requiring invasive mechanical ventilation and/or ECMO: treat for 5 days; if no improvement, may extend for a total duration of 10 days. Hospitalized patients requiring invasive mechanical ventilation and/or ECMO: treat for 10 days. Nonhospitalized patients: treat for 3 days.

Veklury Contraindications

Not Applicable

Veklury Boxed Warnings

Not Applicable

Veklury Warnings/Precautions


Should only be administered in a hospital or in a healthcare setting providing acute care. Obtain eGFR, LFTs, and prothrombin time prior to and during treatment. Consider discontinuing if ALT levels increase to >10×ULN. Discontinue if ALT elevation is accompanied by signs/symptoms of liver inflammation. Monitor for hypersensitivity reactions during and for at least 1hr after infusion; discontinue immediately if significant reactions occur. Renal impairment (eGFR <30mL/min): not recommended. Hepatic impairment. Elderly (monitor). Pregnancy. Nursing mothers.

Veklury Pharmacokinetics

See Literature

Veklury Interactions


Do not administer the diluted solution simultaneously with any other medication. Concomitant chloroquine phosphate or hydroxychloroquine sulfate: not recommended.

Veklury Adverse Reactions

Adverse Reactions

Nausea, increased ALT/AST; hypersensitivity reactions, generalized seizure, rash.

Veklury Clinical Trials

See Literature

Veklury Note

Not Applicable

Veklury Patient Counseling

See Literature